Food and Drug Administration v. Alliance for Hippocratic Medicine

Article III Standing and Challenges to FDA Regulation of Mifepristone

Abstract

In Food and Drug Administration v. Alliance for Hippocratic Medicine, 602 U.S. 367 (2024), the Supreme Court of the United States held unanimously that pro-life physicians and medical associations lacked Article III standing to challenge the Food and Drug Administration’s (FDA) 2016 and 2021 regulatory relaxations of mifepristone, a medication used in early pregnancy termination. Delivered by Justice Kavanaugh, the opinion emphasised that plaintiffs who neither prescribe nor use the drug, and whom the FDA does not compel to act contrary to their conscience, cannot establish the requisite injury-in-fact, traceability, or redressability merely by asserting moral, ideological, or policy objections to the drug’s increased availability to others. The Court rejected speculative theories of “conscience injury” from emergency-room treatment of complications and declined to recognise standing based on organisational expenditures or associational representation without concrete harm to members.

This case note examines the majority’s strict application of standing doctrine as a jurisdictional gatekeeper, its rejection of attenuated causal chains in the post-Dobbs regulatory-litigation environment, and the concurrence by Justice Thomas questioning the constitutional foundations of associational standing. It analyses the procedural history originating in the Northern District of Texas, contrasts the lower courts’ expansive view of injury with the Supreme Court’s narrower conception, and evaluates the decision’s implications for administrative-law challenges, FDA authority over Risk Evaluation and Mitigation Strategies (REMS), and future reproductive-health litigation. The note situates the ruling within broader debates over judicial review of agency expertise, ideological forum-shopping, and the limits of “unregulated parties” seeking to constrain regulation of third parties. While preserving nationwide access to mifepristone under current FDA conditions, the decision leaves open merits questions and signals potential future scrutiny of associational standing and agency action in an appropriate case.